449811-12-5

Basic information

• Product Name: 6-(2,4-Difluorophenoxy)-8-Methyl-2-(Methylthio)pyrido[2,3-d]pyriMidin-7(8H)-one
• Synonyms: 6-(2,4-Difluorophenoxy)-8-Methyl-2-(Methylthio)pyrido[2,3-d]pyriMidin-7(8H)-one
• CAS NO: 449811-12-5
• Molecular Formula: C₁₅H₁₁F₂N₃O₂S
• Molecular Weight: 335.3285464
• Mol File: 449811-12-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform, DMSO
• CAS DataBase Reference: 6-(2,4-Difluorophenoxy)-8-Methyl-2-(Methylthio)pyrido[2,3-d]pyriMidin-7(8H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2,4-Difluorophenoxy)-8-Methyl-2-(Methylthio)pyrido[2,3-d]pyriMidin-7(8H)-one(449811-12-5)
• EPA Substance Registry System: 6-(2,4-Difluorophenoxy)-8-Methyl-2-(Methylthio)pyrido[2,3-d]pyriMidin-7(8H)-one(449811-12-5)

Safety Data

• Hazardous Substances Data: 449811-12-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-(2,4-Difluorophenoxy)-8-Methyl-2-(Methylthio)pyrido[2,3-d]pyriMidin-7(8H)-one is used as an intermediate in the synthesis of Pamapimod (P167500), a selective inhibitor of the α-isoform of p38 MAP kinase. 6-(2,4-Difluorophenoxy)-8-Methyl-2-(Methylthio)pyrido[2,3-d]pyriMidin-7(8H)-one plays a crucial role in the development of new drugs targeting inflammatory diseases and autoimmune disorders, as p38 MAP kinase is a key enzyme involved in these conditions.
Application Reason:
6-(2,4-Difluorophenoxy)-8-Methyl-2-(Methylthio)pyrido[2,3-d]pyriMidin-7(8H)-one's unique structure allows it to be a valuable building block in the synthesis of Pamapimod, which has potential therapeutic applications in treating various diseases. By inhibiting the α-isoform of p38 MAP kinase, Pamapimod can help regulate the immune response and reduce inflammation, making it a promising candidate for the treatment of conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

Upstream product

• 449811-63-6 methyl 2,4-difluorophenoxyacetate 
• 185040-32-8 4-methylamino-2-methylthiopyrimidine-5-carboxaldehyde 
• 17759-30-7 (4-methylamino-2-methylsulfanyl-pyrimidin-5-yl)-methanol 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 76360-82-2 4-methylamino-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester 
• 367-27-1 2,4-difluorophenol 
• 96-32-2 bromoacetic acid methyl ester 
• 1280218-22-5 6-(2,4-difluorophenoxy)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 74-88-4 methyl iodide 
• 717-30-6 2-(2,4-difluorophenoxy)acetic acid ethyl ester 
• 2223-96-3 4-chloro-2-ethylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester 

Downstream Products

• 449808-50-8 6-(2,4-difluorophenoxy)-8-methyl-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 1280218-15-6 6-(2,4-difluorophenoxy)-8-methyl-2-methylamino-8H-pyrido[2,3-d]pyrimidin-7-one 
• 852022-92-5 6-(2,4-difluorophenoxy)-2-isopropylamino-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1280218-16-7 6-(2,4-difluorophenoxy)-8-methyl-2-[(S)-(tetrahydrofuran-3-yl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one 
• 784133-52-4 6-(2,4-difluorophenoxy)-2-(2-hydroxy-2-methylpropylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 759451-95-1 6-(2,4-difluorophenoxy)-2-(2-hydroxy-1,1-dimethylethylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1280218-17-8 3-(2,4-difluorophenoxy)-2-(2-hydroxy-1-hydroxymethylethylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1280218-18-9 2-(2'-methylsulfonylethylamino)-6-(2,4-difluorophenoxy)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one 
• 1280218-54-3 6-(2,4-difluorophenoxy)-8-methyl-2-((R)-1-methyl-2-methylsulfanylethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1280218-19-0 6-(2,4-difluorophenoxy)-2-((R)-2-methanesulfonyl-1-methylethylamino)-8-methyl-8Hpyrido[2,3-d]pyrimidin-7-one 
• 1222660-39-0 6-(2,4-difluorophenoxy)-2-((S)-2-methanesulfonyl-1-methylethylamino)-8-methyl-8Hpyrido[2,3-d]pyrimidin-7-one 
• 1280218-55-4 2-(1-benzylpiperidin-4-ylamino)-6-(2,4-difluorophenoxy)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1280218-56-5 6-(2,4-difluorophenoxy)-8-methyl-2-(piperidin-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1280218-20-3 2-(1-acetylpiperidin-4-ylamino)-6-(2,4-difluorophenoxy)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 

Relevant articles and documents

Development of radioiodinated pyrimidinopyridone derivatives as targeted imaging probes of activated p38α for single photon emission computed tomography

Objective: p38α, a member of the mitogen-activated protein kinase superfamily, is ubiquitously expressed in a variety of mammalian cells. Activated p38α induces inflammatory responses to external stimuli, suggesting that non-invasive detection of activate

Inhibitor containing fused ring derivative as well as preparation method and application thereof

The invention relates to an inhibitor containing fused ring derivative as well as a preparation method and application thereof. Particularly, the invention relates to a compound as shown in a generalformula (I), a preparation method thereof, a pharmaceuti

INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE

The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disea

Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes

Activation of various interacting stress kinases, particularly the c-Jun N-terminal kinases (JNK), and a concomitant phosphorylation of insulin receptor substrate 1 (IRS-1) at serine 307 play a central role both in insulin resistance and in β-cell dysfunction. IRS-1 phosphorylation is stimulated by elevated free fatty acid levels through different pathways in obesity. A series of novel pyrido[2,3-d]pyrimidin-7-one derivatives were synthesized as potential antidiabetic agents, preventing IRS-1 phosphorylation at serine 307 in a cellular model of lipotoxicity and type 2 diabetes.

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl) propylamino]-8-methyl-8 H -pyrido[2,3- d ]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2 H -pyran-4-ylamino)pyrido[2,3- d ]pyrimidin-7(8 H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase

The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38α, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.